Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 4811 | 7.44 |
09:36 ET | 1300 | 7.37 |
09:38 ET | 648 | 7.36 |
09:39 ET | 100 | 7.36 |
09:50 ET | 150 | 7.36 |
10:01 ET | 6865 | 7.33 |
10:15 ET | 700 | 7.33 |
10:17 ET | 500 | 7.36 |
10:21 ET | 200 | 7.3786 |
10:26 ET | 1164 | 7.4 |
10:32 ET | 314 | 7.409 |
10:35 ET | 2200 | 7.4299 |
10:37 ET | 100 | 7.41 |
10:39 ET | 100 | 7.41 |
10:44 ET | 100 | 7.39 |
10:51 ET | 400 | 7.4 |
10:57 ET | 100 | 7.39 |
11:02 ET | 300 | 7.4 |
11:11 ET | 771 | 7.33 |
11:13 ET | 1000 | 7.34 |
11:27 ET | 100 | 7.34 |
11:31 ET | 100 | 7.355 |
11:33 ET | 100 | 7.36 |
11:40 ET | 100 | 7.36 |
11:42 ET | 800 | 7.365 |
11:44 ET | 100 | 7.37 |
11:47 ET | 100 | 7.385 |
11:51 ET | 200 | 7.37 |
11:54 ET | 100 | 7.385 |
12:00 ET | 161 | 7.3864 |
12:02 ET | 1805 | 7.37 |
12:05 ET | 200 | 7.37 |
12:16 ET | 100 | 7.35 |
12:27 ET | 5219 | 7.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 164.4M | -0.7x | --- |
bluebird bio Inc | 172.0M | -1.2x | --- |
Sagimet Biosciences Inc | 170.1M | -3.9x | --- |
Abeona Therapeutics Inc | 180.4M | -1.3x | --- |
Atossa Therapeutics Inc | 163.5M | -5.3x | --- |
Outlook Therapeutics Inc | 165.5M | -0.6x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $164.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.13 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.